ASCO: Bristol Myers' KRAS confirmatory data avoid Amgen's flaws but leave FDA prospect unclearASCO: Bristol Myers' KRAS confirmatory data avoid Amgen's flaws but leave FDA prospect unclear - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on June 3, 2024 at 5:48 AM in business No comments 32